Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL246591

CCCC[N+]1(C)CCCC1.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 2/20 0.41
LMNA P02545 3/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
KCNH2 Q12809 7/20 0.37
APOBEC3A P31941 2/20 0.34
APOBEC3G Q9HC16 2/20 0.34
KMT2A Q03164 1/20 0.34
ACHE P22303 3/20 0.33
EPHX1 P07099 1/20 0.33
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL30697434 1.00 BBOX1 (0.41) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL717623 0.98 BBOX1 (0.40) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL318063 0.98 BBOX1 (0.40) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL30331399 0.95 LMNA (0.40) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL1535096 0.93 LMNA (0.42) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL30330523 0.93 LMNA (0.42) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL3820014 0.93 LMNA (0.42) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL30330764 0.92 LMNA (0.41) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL4166764 0.92 LMNA (0.41) BBOX1LMNACYP3A4TSHRTDP1
Trifluoromethanesulfonic Acid SCHEMBL29252614 0.92 LMNA (0.41) BBOX1LMNACYP3A4TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099153-A1 DEVICE CAPABLE OF BONDING AND DEBONDING ON DEMAND TESA SE (DE) 2026-05-15 WO claimed
EP-4705295-A2 MULTIFUNCTIONAL COMPOUND CORE FOR ACTIVE AGENTS AND USES THEREOF The University of North Carolina at Chapel Hill (US) 2026-03-11 EP claimed
US-20260015748-A1 CHEMICALLY FACILITATED ELECTROCHEMICAL METHODS FOR RECOVERY OF RARE EARTH ELEMENTS BATTELLE ENERGY ALLIANCE LLC (US) 2026-01-15 US claimed
WO-2025108961-A1 SOLID ELECTROLYTES AND METHOD FOR MANUFACTURING THE SAME SOLITHOR (BE) 2025-05-30 WO claimed
WO-2025104146-A1 SOLID ELECTROLYTE SEPARATORS AND METHOD FOR MANUFACTURING THE SAME SOLITHOR (BE) 2025-05-22 WO claimed
WO-2025090284-A1 ELECTROLYTE COMPRISING SOLVENT WITH NON-FLUORINE HALOGEN SUBSTITUTE AND BATTERIES COMPRISING SAME FACTORIAL INC. (US) 2025-05-01 WO claimed
WO-2025049222-A1 ELECTROLYTE COMPRISING CYCLIC QUATERNARY AMMONIUM IONIC LIQUID AND SOLVENT WITH HIGH BOILING POINT AND BATTERIES COMPRISING SAME FACTORIAL INC. (US) 2025-03-06 WO claimed
US-12172147-B2 Catalyst composition for selective hydrogenation with improved characteristics Sud Chemie, Inc. (US) 2024-12-24 US claimed
US-12172148-B2 Catalyst composition for selective hydrogenation with improved characteristics Sud Chemie, Inc. (US) 2024-12-24 US claimed
US-12157287-B2 Variable emissivity surfaces THE UNIVERSITY OF MANCHESTER (GB) 2024-12-03 US claimed
EP-1869061-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY Combimatrix Corporation (US) 2007-12-26 EP claimed
US-20070181856-A1 Conductive wet coating composition and thin-film prepared therefrom SAMSUNG DISPLAY CO., LTD. (KR) 2007-08-09 US claimed
US-20070176148-A1 Organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2007-08-02 US claimed
EP-1805206-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE Combimatrix Corporation (US) 2007-07-11 EP claimed
US-20070034513-A1 Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array COMBIMATRIX CORPORATION 2007-02-15 US claimed
WO-2007006418-A1 IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-01-18 WO claimed
WO-2006131234-A1 COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-12-14 WO claimed
WO-2006105037-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY COMBIMATRIX CORPORATION (US) 2006-10-05 WO claimed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 WO claimed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12172147-B2 Catalyst composition for selective hydrogenation with improved characteristics BET1, EP300, H1-2 BBOX1 689/4885LMNA 3071/4885CYP3A4 1780/4885
US-12172148-B2 Catalyst composition for selective hydrogenation with improved characteristics BET1, EP300, H1-2 BBOX1 689/4885LMNA 3071/4885CYP3A4 1780/4885
US-20260015748-A1 CHEMICALLY FACILITATED ELECTROCHEMICAL METHODS FOR RECOVERY OF RARE EARTH ELEMENTS RPS7, SRSF7, XPO7 BBOX1 4542/4885LMNA 1492/4885CYP3A4 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.